Detalhe da pesquisa
1.
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma.
Haematologica;
107(5): 1144-1152, 2022 05 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34289656
2.
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.
Blood;
133(20): 2121-2129, 2019 05 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30770396
3.
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial.
Eur Urol;
2024 May 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38782695
4.
Retrospective characterization of nodal marginal zone lymphoma.
Blood Adv;
7(17): 4838-4847, 2023 09 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37307213
5.
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.
Blood Adv;
7(17): 5172-5186, 2023 09 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37078708
6.
Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience.
Leuk Lymphoma;
63(4): 876-884, 2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34784853
7.
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
Lancet Haematol;
8(12): e879-e890, 2021 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34826411